Table 1.
Characteristics of study population, IBD patients versus controls.
| IBD patients | Controls | P value | |
|---|---|---|---|
| Number | 33,131 | 198,825 | |
| Age category (%) | |||
| 20–29 | 20.7 | 20.7 | |
| 30–39 | 21.9 | 21.9 | |
| 40–49 | 21.1 | 21.1 | |
| 50–59 | 18.9 | 18.9 | |
| 60–69 | 10.8 | 10.8 | |
| 70–80 | 6.6 | 6.6 | |
| Sex (%) | |||
| Male | 60.7 | 60.7 | |
| Female | 39.3 | 39.3 | |
| Disease phenotype (%) | |||
| Crohn’s disease | 29.9 | ||
| Ulcerative colitis | 70.0 | ||
| Unspecified | 0.1 | ||
| Co-morbidities (%) | 23.0 | 26.2 | < 0.001 |
| Hypertension | 17.2 | 20.8 | < 0.001 |
| Diabetes Mellitus | 11.5 | 13.8 | < 0.001 |
| Cardiovascular disease | 5.1 | 6.3 | < 0.001 |
| Cerebrovascular disease | 2.8 | 2.9 | 0.087 |
| Heart failure | 1.4 | 1.5 | 0.283 |
| Atrial fibrillation | 0.8 | 0.8 | 0.249 |
| Chronic kidney disease | 1.0 | 0.9 | 0.027 |
| Medications (ever use, %) | |||
| 5-ASA | 90.5 | ||
| Corticosteroids | 59.2 | ||
| Immunomodulators | 29.2 | ||
| Anti-TNF-α agents | 8.6 | ||
Values are expressed as means ± standard deviation or percentages.
IBD inflammatory bowel disease; 5-ASA 5-aminosalicylic acid; Anti-TNF-α anti-tumor necrosis factor α.